Tesamorelin 5mg

While CJC-1295 Without DAC 10mg, CJC-1295 With DAC 10mg, and Sermorelin 2mg all use only the first 29 amino acids of native GHRH, tesamorelin 5mg contains the full 44-amino-acid sequence, which makes it suitable for structure-function studies comparing full-length and truncated GHRH analogues. GHRH(1-29) already contains the sequence required for receptor activity, so any difference between full-length and truncated analogues is an experimental question rather than an established advantage.

Evidence status: tesamorelin is the active substance of Egrifta, approved in the United States in 2010 to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, on the basis of randomised controlled trials (Falutz et al., N Engl J Med, 2007). The EU marketing-authorisation application was withdrawn in 2012 before a final opinion. These clinical data concern a licensed formulation and patient population; they do not describe or verify the research material supplied here.

The 5mg format is appropriate for pilot investigations, method development, assay validation, and first-time tesamorelin research. For established programmes requiring larger quantities and full dose-response gradients, Tesamorelin 10mg provides the advanced format. For comparative GHRH receptor research studying the truncated 29-amino acid analogues alongside the full-length sequence, CJC-1295 Without DAC 10mg and Sermorelin 2mg are the appropriate complementary compounds. Ipamorelin 5mg acts at GHS-R1a rather than the GHRH receptor; in whole-animal designs both classes raise GH, so combined arms need appropriate controls.

Mechanism background and comparison tables across the GHRH analogues are available in the Tesamorelin 5mg research guide on the Ascend Peptides UK blog.

No certificate is published yet for the 5mg format; the 10mg report does not cover 5mg vials.

Storage requirements for Tesamorelin are currently being verified with the manufacturer. Ascend Peptides UK does not publish reconstitution, solvent or in-use instructions; these are decisions for your own validated laboratory protocol.